Bone marrow stromal cells as a genetic platform for systematic delivery of therapeutic proteins in vivo: Human factor IX model

Journal of Gene Medicine

Volumn 5, Issue 1, 2003, Pages 11-17

  Krebsbach, Paul H ^a   Zhang, Kezhong ^b   Malik, Ajay K ^b   Kurachi, Kotoku ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow stromal cells; Gene therapy; Hemophilia; Mesenchymal stem cells; Osteogenesis

Indexed keywords

BLOOD CLOTTING FACTOR 9; PROTEIN; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY OSSICLE; BONE MARROW CELL; CELL ACTIVITY; CELL BASED GENE THERAPY; CELL SPECIFICITY; CELL TRANSPLANTATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA MODIFICATION; DRUG MECHANISM; GENE CONSTRUCT; GENETIC TRANSDUCTION; HEMOPHILIA B; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; STROMA CELL; SUBCUTANEOUS TISSUE; SWINE; WESTERN BLOTTING; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; RETROVIRUS;

ANIMALS; BONE MARROW CELLS; FACTOR IX; GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE; STROMAL CELLS; SWINE; TRANSDUCTION, GENETIC;

EID: 0038681076     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.292     Document Type: Article

References (56)

1. Anderson WF. Human gene therapy. Nature 1998; 392 25-30.
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
3. Naffakh N, Pinset C, Montarras D, et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 1996; 7: 11-21.
4. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
5. Gage FH. Gell therapy. Nature 1998; 392: 18-24.
6. Blau HM, Springer ML. Gene therapy - a novel form of drug delivery. N Engl J Med 1995; 333: 1204-1207.
7. Yao SN, Smith KJ, Kurachi K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther 1994; 1: 99-107.
8. Turgeman G, Pittman DD, Muller R, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy, J Gene Med 2001; 3: 240-251.
9. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci U S A 1991; 88: 1330-1334.
10. Anson DS, Bielicki J, Hopwood JJ. Correction of mucopolysaccharidosis type I fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene. Hum Gene Ther 1992; 3: 371-379.
11. Liu JM, Kim S, Read EJ, et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther 1999; 10: 2337-2346.
12. Lim B, Apperley JF, Orkin SH, Williams DA. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A 1989; 86: 8892-8896.
13. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988; 331: 35-41.
14. Overturf K, Al-Dhalimy M, Manning K, Ou CN, Finegold M, Grompe M. Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 1998; 9: 295-304.
15. Kay MA, Baley P, Rothenberg S, et al. Expression of human alpha-1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci U S A 1992; 89: 89-93.
16. Gupta S, Vemuru RP, Lee CD, Yerneni PR, Aragona E, Burk RD. Hepatocytes exhibit superior transgene expression after transplantation into liver and spleen compared with peritoneal cavity or dorsal fat pad: implications for hepatic gene therapy. Hum Gene Ther 1994; 5: 959-967.
17. Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury, J Neurosci 1997; 17: 5560-5572.
18. Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor GNTF in a monkey model of Huntington's disease. Nature 1997; 386: 395-399.
19. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091-2107.
20. Mannucci PM, Tuddenbam EG. The hemophilias: progress and problems. Semin Hematol 1999; 36(Suppl 7): 104-117.
21. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A 1982; 79 6461-6464.
22. Kay MA, High K. Gene therapy for the hemophilias. Proc Natl Acad Sci U S A 1999; 96: 9973-9975.
23. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-119.
24. Hao QL, Malik P, Salazar R, Tang H, Gordon EM, Kohn DB. Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Hum Gene Ther 1995; 6: 873-880.
25. Chuah MK, Van Damme A, Zwinnen H, et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000; 11: 729-738.
26. Cherington V, Chiang GG, McGrath CA, et al. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Hum Gene Ther 1998; 9: 1397-1407.
27. Gordon EM, Skotzko M, Kundu RK, et al. Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. Hum Gene Ther 1997; 8: 1385-1394.
28. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
29. Krebsbach PH, Kuznetsov SA, Bianco P, Gehron Robey P. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral Bio Med 1999; 10: 165-181.
30. Goshima J, Goldberg VM, Caplan AI. The osteogenic potential of culture-expanded rat marrow mesenchymal cells assayed in vivo in calcium phosphate ceramic blocks. Clin Orthop 1991; 262: 298-311.
31. Gazit D, Turgeman G, Kelley P, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy, J Gene Med 1999; 1: 121-133.
32. Krebsbach PH, Kuznetsov SA, Satomura K, Emmons RV, Rowe DW, Robey PG. Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation 1997; 63: 1059-1069.
33. Kuznetsov SA, Krebsbach PH, Satomura K, et al. Single-colony derived strains of human stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997; 12: 1335-1347.
34. Malik AK, Wang J-M, Kurachi K. Effects of a second intron on recombinant MFG retroviral vector. Arch Virol 2001; 146(3): 601-609.
35. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector [see comments]. Nat Genet 1993; 3: 219-223.
36. Yao SN, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A 1992; 89: 3357-3361.
37. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci U S A 1991; 88: 8101-8105.
38. Stanley TB, Wu SM, Houben RJ, Mutucumarana VP, Stafford DW. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry 1998; 37: 13 262-13 268.
39. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75: 1753-1762.
40. Wang JM, Zheng H, Blaivas M, Kurachi K. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood 1997; 90: 1075-1082.
41. Friedenstein A, Kuralesova AI. Osteogenic precursor cells of bone marrow in radiation chimeras. Transplantation 1971; 12: 99-108.
42. Friedenstein AJ, Petrakova KV, Kuralesova AI, Frolova GP. Heterotopic transplants of bone marrow. Analysis of precursor cells for osteogenic and hemopoietic tissues. Transplantation 1968; 6: 230-247.
43. Friedenstein AJ, Ivanov-Smolenski AA, Chailakhyan RK, et al. Origin of bone marrow stromal mechanocytes in radiochimeras and heterotopic transplants. Exp Hematol 1978; 6: 440-444.
44. Hotta T, Murate T, Utsumi M, Hirabayashi N, Yamada H. Origin of hemopoietic and stromal cells in subcutaneous femur implants. Exp Hematol 1983; 11: 107-113.
45. Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci U S A 1991; 88: 2236-2240.
46. Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117 765-771.
47. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism, J Clin Invest 1996; 98: 1619-1625.
48. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244.
49. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
50. Hagstrom JN, Couto LB, Scallan G, et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 2000; 95: 2536-2542.
51. Roman M, Axelrod JH, Dai Y, Naviaux RK, Friedmann T, Verma IM. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet 1992; 18: 247-258.
52. Wang JM, Zheng H, Sugahara Y, et al. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Hum Gene Ther 1996; 7: 1743-1756.
53. Hurwitz DR, Kirchgesser M, Merrill W, et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997; 8: 137-156.
54. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94: 1426-1431.
55. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154-158.
56. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 168-174.